1

Viela Bio

Autoimmune and severe inflammation

www.vielabio.com

HBM contact: Dr Emil Bujak

Company status: private

 A clinical-stage biotech pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease. Viela’s lead asset is inebilizumab, a breakthrough treatment for Neuromyelitis optica syndrome spectrum disorder patients.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171